XML 21 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
ASSETS    
Cash and cash equivalents $ 194,385 $ 214,054
Accounts receivable 323 20
Accounts receivable - related parties 5,524  
Research and development incentives receivable 4,541 6,229
Prepaid expenses and other current assets 8,268 6,462
Total current assets 213,041 226,765
Goodwill 12,209 12,630
Property and equipment, net 7,957 1,829
Intangible assets, net 28,269 31,430
Right of use assets, net 7,753 7,257
Other assets 976 804
Total assets 270,205 280,715
Current liabilities:    
Accounts payable 3,748 2,419
Accrued expenses and other current liabilities 8,061 7,875
Deferred revenue   182
Operating lease liability - current 433 523
Debt   159
Total current liabilities 12,242 11,158
Operating lease liability 8,340 6,540
Contingent consideration 1,711 2,371
Other non-current liabilities 965  
Deferred tax liability, net 3,746 8,084
Total liabilities 27,004 28,153
Commitments and contingencies
Shareholders' equity:    
Ordinary shares, £0.000025 nominal value; 37,683,531 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 37,188,730) 1 1
Additional paid-in capital 379,504 369,103
Accumulated deficit (103,243) (108,585)
Accumulated other comprehensive loss - foreign currency translation adjustments (33,460) (8,488)
Total shareholders' equity attributable to Vaccitech plc shareholders' 242,896 252,125
Noncontrolling interest 305 437
Total shareholders' equity 243,201 252,562
Total liabilities and shareholders' equity 270,205 280,715
Deferred A shares    
Shareholders' equity:    
Deferred shares 86 86
Deferred B shares    
Shareholders' equity:    
Deferred shares 8 8
Deferred C shares    
Shareholders' equity:    
Deferred shares [1] $ 0 $ 0
[1] Indicates amount less than one thousand